03.02.26 -- Navigating Conflicting Raw Material Preferences With Your CDMO

Digital CMC platforms address tech transfer inefficiencies by unifying process knowledge, reducing compliance risk, and significantly compressing CDMO onboarding timelines.

Rapid, low‑cost checks can catch construct issues that limit vector manufacturing, enabling early fixes to improve titers, avoid delays, and accelerate gene therapy programs.

Advanced NGS bioinformatics pipelines and curated viral databases enhance the detection of adventitious agents. Learn how cloud-based protocols ensure rigorous safety assessments and maintain compliance.

Watch a unified roadmap for drug product development, outlining phase‑appropriate studies, QTTP importance, and key requirements from preclinical stages through commercialization.

Suspension-adapted cell lines enable cost-efficient AAV and LVV production. These tools ensure regulatory compliance and high yields while maintaining stability for advanced therapies.

Integrated analytical capabilities within a CDMO are increasingly preferred to overcome challenges associated with outsourcing analysis in biopharma development and manufacturing.

To prevent path-to-market setbacks, it is critical to develop a Chemistry, Manufacturing, and Controls strategy that proactively identifies scientific and compliance gaps, as well as mitigates risk.

Discover how genome engineering and iPSCs are being used to overcome the critical challenges of durability and host immune clearance in both clinical and preclinical settings for allogeneic cell therapies.